PPIB and COVID-19: Continued adaptation of COVID-19 vaccines beyond, for example, XBB.1.5 vaccines to maintain protection is supported by extensive B cell receptor repertoire analysis9 but may be of clinical value only in populations at risk for severe COVID-19.